Dexcom Touts G7 As ‘The Most Accurate CGM’ As It Prepares For US Launch
The US FDA has granted authorization to Dexcom to market its G7 continuous glucose monitor, which the company will launch in the next couple of months.
You may also be interested in...
Dexcom Raises Another Billion, But Why?
The company’s cash balance at the end of last quarter was more than enough to weather most storms – so why has Dexcom raised more money?
News We’re Watching – Medicare Covers Dexcom CGM; New Mpox EUA; $106M Patent Verdict Against Medtronic
Medicare announced coverage for the Dexcom G7 continuous glucose monitor, as well as a breast cancer indication for Natera Inc.’s Signatera; the FDA authorized a new monkeypox test; the FDA issued a warning letter to a Texas masks firm; and a new report says NIST labs are failing behind.
Dexcom Doubles Down On Jonas Branding To Hail G7 Launch
Dexcom is commemorating the US launch of its G7 continuous glucose monitor with an expensive ad spot during the Super Bowl.